1. Home
  2. FLNC vs URGN Comparison

FLNC vs URGN Comparison

Compare FLNC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluence Energy Inc.

FLNC

Fluence Energy Inc.

HOLD

Current Price

$15.20

Market Cap

2.1B

Sector

Miscellaneous

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$43.55

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNC
URGN
Founded
2018
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
FLNC
URGN
Price
$15.20
$43.55
Analyst Decision
Hold
Strong Buy
Analyst Count
17
7
Target Price
$15.71
$29.29
AVG Volume (30 Days)
8.8M
692.0K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,262,830,000.00
$1,128,000.00
Revenue This Year
$51.23
$129.09
Revenue Next Year
$21.30
$70.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$15.86
52 Week High
$33.51
$43.93

Technical Indicators

Market Signals
Indicator
FLNC
URGN
Relative Strength Index (RSI) 40.40 80.04
Support Level $14.28 $17.89
Resistance Level $16.40 N/A
Average True Range (ATR) 1.38 2.14
MACD -0.19 0.14
Stochastic Oscillator 27.43 97.16

Price Performance

Historical Comparison
FLNC
URGN

About FLNC Fluence Energy Inc.

Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: